Indication
Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
Medicine details
- Medicine name:
- abrocitinib (Cibinqo)
- SMC ID:
- SMC2431
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Publication due date:
- 13 June 2022
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 04 April 2022